Alembic Pharmaceuticals Reports Resilient Q1 FY27 Results; Revenue Jumps 26%

Alembic Pharmaceuticals Reports Resilient Q1 FY27 Results; Revenue Jumps 26%​

Alembic Pharmaceuticals Limited announced its consolidated financial results for the first quarter of fiscal year 2027 (Q1 FY27) ended June 30, 2026, showcasing broad-based growth across its businesses. The company reported a notable increase in revenue and profitability during the period.

The pharmaceuticals firm saw its revenue from operations rise by 26% year over year (YoY), reaching Rs 2150 Cr. Profit After Tax stood at Rs 173 Cr, marking a 12% YoY improvement. Furthermore, EBITDA pre R&D increased to Rs 523 Cr, with the margin stabilizing at 24%.

Segmental Performance Highlights​

The company detailed strong performance across its key operating segments, including India Branded Business, International Operations, and API segment growth.

In the domestic market, the India Branded Business grew by 7% YoY, generating Rs 642 Cr in revenue for the quarter. This performance was supported by robust expansion in Gynaecology, Gastrology, and Ophthalmology, alongside encouraging results from the Animal healthcare segment. The company introduced three new products during the quarter.

International operations showed significant momentum. US Formulation achieved a substantial growth of 49%, contributing Rs 778 Cr to revenue. During this period, the company executed seven market launches in the United States. Ex-US Generics grew by 17% to Rs 383 Cr, and Alembic received 10 ANDA approvals during the quarter.

The API business segment expanded by 33%, generating Rs 346 Cr.

Consolidated Revenue Breakdown​

The following table summarizes the revenue from operations for the formulation segment, comparing Q1 FY26 with Q1 FY27 results:

Management Commentary​

Commenting on the results, Mr Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, stated that the company commenced FY27 on a strong footing. He attributed the performance to healthy volume growth and successful new product introductions across its businesses. The US business provided strong momentum, complementing steady growth recorded in other international markets. Mr Amin emphasized that the management remains focused on driving sustainable long-term growth by strengthening the product portfolio and advancing the pipeline.

APLLTD Stock Price Movement​

Shares of Alembic Pharmaceuticals Limited are edging higher to ₹808.75 as of 3:03 PM today, gaining 0.37% in live trading. The pharmaceutical stock saw active market interest with a traded volume totaling 435,328 shares during the ongoing session.